Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$536.87 USD
+5.01 (0.94%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $536.96 +0.09 (0.02%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$536.87 USD
+5.01 (0.94%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $536.96 +0.09 (0.02%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Abbott (ABT) Tops Q2 Earnings Estimates, Lifts EPS Guidance
by Zacks Equity Research
Abbott (ABT) registers strong Cardiovascular and Neuromodulation sales on double-digit growth in Electrophysiology, Heart Failure and Structural Heart.
Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.
The Zacks Analyst Blog Highlights: Northrop Grumman, Thermo Fisher Scientific, Newmont Goldcorp, Starbucks and CME
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Northrop Grumman, Thermo Fisher Scientific, Newmont Goldcorp, Starbucks and CME
Can Fed Put Counter Potential Negative Q2 Earnings? 5 Picks
by Nalak Das
Fed's rate cut will not only make cheaper funds available to businesses and stock market investors, but also U.S. dollar less expensive in the international market.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: JPMorgan, Thermo Fisher, Broadcom, Marriott and Global Payments
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Thermo Fisher, Broadcom, Marriott and Global Payments
Top Stock Reports for JPMorgan, Thermo Fisher & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Thermo Fisher (TMO) and Broadcom (AVGO).
Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics
by Zacks Equity Research
The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.
Thermo Fisher Abandons Gatan Deal in Want of European Nod
by Zacks Equity Research
Thermo Fisher (TMO) and Roper will carry on with their current long-term supply agreement.
Why Is Thermo Fisher (TMO) Up 0.6% Since Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site
by Zacks Equity Research
The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Thermo Fisher Scientific Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO) has been struggling lately, but the selling pressure may be coming to an end soon.
The Zacks Analyst Blog Highlights: Mastercard, PayPal, Thermo Fisher, Starbucks and Simon Property
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, PayPal, Thermo Fisher, Starbucks and Simon Property
Top Research Reports for Mastercard, PayPal & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), PayPal (PYPL) and Thermo Fisher (TMO).
Zacks.com featured expert Kevin Matras highlights: Foot Locker, Thermo Fisher Scientific, SS&C Technologies, Columbia Sportswear and Comcast
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Foot Locker, Thermo Fisher Scientific, SS&C Technologies, Columbia Sportswear and Comcast
Thermo Fisher (TMO) Beats on Q1 Earnings, Raises '19 View
by Zacks Equity Research
Thermo Fisher (TMO) reports strong Laboratory Products and Services performance, flaunting robust global demand.
5 Top-Ranked Cheap Dividend Growth Stocks
by Sweta Killa
While there are several dividend stocks that could provide capital appreciation, honing in on stocks with a history of dividend growth leads to a healthy portfolio with a greater scope of capital appreciation.
What's in Store for Tandem Diabetes' (TNDM) Q1 Earnings?
by Zacks Equity Research
The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.
Why Earnings Season Could Be Great for Thermo Fisher (TMO)
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
TMO or ABMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TMO vs. ABMD: Which Stock Is the Better Value Option?
Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
Can Boston Scientific's (BSX) Steady Growth Aid Q1 Earnings?
by Zacks Equity Research
We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.
Can Five Elements Drive Quest Diagnostics (DGX) Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) seems in sync with its strategy to expedite growth and operational excellence.